Olmesartan Medoxomilo + Hidroclorotiazida Pharmakern (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomilo + Hidroclorotiazida Pharmakern, is an angiotensin II receptor blocker presented as a oral tablet for hypertension management in adults. It combines olmesartan medoxil with hydrochlorothiazide to improve blood pressure control.

GNH USA supplies Olmesartan Medoxomilo + Hidroclorotiazida Pharmakern as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan Medoxomilo + Hidroclorotiazida Pharmakern is used in cardiovascular therapy to lower blood pressure and reduce cardiovascular risk. - Hypertension: Helps lower systolic and diastolic blood pressure in patients with primary hypertension. - Heart failure: Assists in managing fluid overload and blood pressure in certain heart failure patients. - Diabetic nephropathy: Provides renal protection by controlling hypertension in patients with type 2 diabetes.

Adverse reactions may occur with any antihypertensive regimen and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium)

Serious or Rare Side Effects: - Angio‑edema - Severe hypotension - Acute kidney injury - Hyperkalemia - Liver function abnormalities - Severe skin reactions such as Stevens‑Johnson syndrome

Before prescribing Olmesartan Medoxomilo + Hidroclorotiazida, clinicians should evaluate patient history and monitor relevant parameters. - Renal function: Assess baseline creatinine and eGFR before initiating therapy. - Electrolytes: Monitor serum potassium and sodium levels regularly. - Pregnancy: Contraindicated in the second and third trimesters due to fetal toxicity. - Concomitant NSAIDs: Use with caution as they may reduce antihypertensive efficacy and affect renal function. - Hypersensitivity: Discontinue if signs of angio‑edema or severe rash develop. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan Medoxomilo + Hidroclorotiazida may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Alkaline‑alkaline ​  :  Co‑co   ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​ - Potassium‑sparing diuretics: May cause hyper‑kalaemia. - Lithium: May increase lithium levels and toxicity risk. - ACE inhibitors or other ARBs: Additive hypotensive effect; monitor blood pressure.

Moderate Interactions (Monitor Closely): - NSAIDs: May blunt antihypertensive response and affect renal function. - Antidiabetic drugs: May require dose adjustment due to enhanced glucose‑lowering effect. - CYP‑3A4 inhibitors: May increase olmesartan exposure. - Loop diuretics: Combined diuretic effect may lead to excessive volume depletion. - Antacids containing magnesium or aluminium: May reduce absorption of olmeset‑